RxDoctor Payments DataLook up a doctor →

Rebecca Hood, APRN

Family · Monroe, LANPI 1649880675

Payments from drug & device makers

$14,529in general payments, 2019–2025

Across 547 payments — averaging $26.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Onmark, Inc.$4K
  • Johnson & Johnson$817
  • AstraZeneca$683
  • Novartis$665
  • Daiichi Sankyo Inc.$661
  • Merck$596
  • plus $7K from 54 others

What the payments were for

  • Travel & lodging$2,27416%
  • Food & beverage$11,89782%
  • Education$3392%
  • Gifts$200%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Onmark, Inc.10$3,732
Johnson & Johnson(2 entities)39$817
AstraZeneca(2 entities)37$683
Novartis36$665
Daiichi Sankyo Inc.31$661
Merck27$596
Incyte Corporation30$546
Eisai Inc.21$419
AbbVie15$412
Bristol Myers Squibb20$355
Bayer17$346
Amgen15$307
GSK13$256
Takeda Pharmaceuticals U.S.A., Inc.11$240
Pfizer14$235
Lilly USA, LLC12$219
Seagen Inc.11$218
Tempus AI, Inc8$211
Ipsen Biopharmaceuticals, Inc11$209
Exelixis Inc.13$201
Beigene USA, Inc.9$181
Genentech USA, Inc.10$181
Astellas Pharma US Inc9$176
Stemline Therapeutics Inc.7$175
Sanofi9$158
EMD Serono, Inc.9$145
Regeneron Healthcare Solutions, Inc.6$133
E.r. Squibb & Sons, L.L.C.6$118
Pharmacosmos Therapeutics Inc.6$113
Boehringer Ingelheim5$105
Pharmaessentia USA Corporation4$99
Gilead5$89
Servier Pharmaceuticals LLC4$88
Jazz Pharmaceuticals Inc.3$83
Puma Biotechnology, Inc.5$83
Genmab U.S., Inc.4$80
Blueprint Medicines Corporation4$79
Recordati_rare_diseases_inc.3$77
Adaptive Biotechnologies Corporation4$77
AVEO Pharmaceuticals, Inc.4$76
Rigel Pharmaceuticals, Inc.4$73
Sanofi-aventis U.S. LLC1$65
Agios Pharmaceuticals, Inc.3$60
Teva Pharmaceuticals USA, Inc.4$60
Evofem Biosciences, Inc.1$59
Tersera Therapeutics LLC2$59
Sobi, Inc3$54
Mirati Therapeutics, Inc.3$51
Pharmacyclics LLC, An Abbvie Company2$45
Beone Medicines USA, Inc.2$43
Taiho Oncology, Inc.2$43
ADC Therapeutics America, Inc.2$37
G1 Therapeutics, Inc.2$37
Progenics Pharmaceuticals, Inc.1$31
Immunocore Limited1$31
Legend Biotech USA Inc.1$27
Morphosys, US Inc.1$25
Geron Corporation1$21
Heron Therapeutics, Inc.1$19
TG Therapeutics, Inc.1$19

How this compares

$14,529 in reported general payments places this provider in the 95th percentile of 3,610 family providers in Louisiana.

See all family providers in Louisiana

Medicare billing

Part B allowed, 2024
$40,508
Medicare patients
254
Services billed
958

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lenalidomide28$374,615
ImbruvicaIbrutinib21$334,826
RevlimidLenalidomide15$261,052
CalquenceAcalabrutinib Maleate11$153,905
Abiraterone Acetate27$97,028
EliquisApixaban87$58,170
XareltoRivaroxaban18$15,281
ZarxioFilgrastim-Sndz11$13,189
Imatinib Mesylate13$8,862
Erlotinib Hcl15$5,478
Letrozole140$5,317
Exemestane24$3,027
ValacyclovirValacyclovir Hcl30$1,232
Dexamethasone36$1,206
Oxycodone Hcl62$838

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Pharmacyclics LLC, An Abbvie CompanyImbruvica$45$334,82621 claims
Bristol Myers SquibbRevlimid$355$261,05215 claims
AstraZenecaCalquence$683$153,90511 claims
PfizerEliquis$235$58,17087 claims
Johnson & JohnsonXarelto$817$15,28118 claims
Teva Pharmaceuticals USA, Inc.Acyclovir$60$10819 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,610 family providers in Louisiana.

Other family in Monroe

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →